Download PDF
Thromb Haemost 1975; 34(03): 613-622
DOI: 10.1055/s-0038-1651451
Original Article
Schattauer GmbH

The Position of Long-Term Stimulation of the Endogenous Fibrinolytic System: Present Achievements and Clinical Perspectives[*]

M Verstraete
1   Laboratorium Bloedstolling, Departement Medische Navorsing, Universiteit Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 01 July 1975

accepted 01 July 1975

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

Summary

There is reasonable evidence in favour of the assumption made by several investigators that patients with thrombosis of arteries or veins, or cutaneous vasculitis have, very often, a low spontaneous fibrinolytic activity. The use of long-term activators of blood fibrinolytic activity such as diguanides and anabolic steroids was shown to increase the activators to normal levels in the above mentioned and other conditions. In many instances, but not all, this induced increase of fibrinolytic activity resulted in an improved clinical condition and prevention of venous thrombosis. At the present time, there are indications that new and more powerful compounds will cause a sustained stimulation of the fibrinolytic potential and be useful for the prevention of thrombotic disorders. Some of these compounds, which have been investigated only partly at the clinical level, appear to approach the requirements of a useful oral fibrinolytic agent and it is hoped that from these observations further improvements in this range of drugs will be made.

* Presented at the Postgraduate Course and Workshop “Progress in Fibrinolysis”,. Milan, March 6–8, 1975.


 

  • References

  • 1 Allenby F, Flug J. J, Boaedman L, and Calnan J. S. 1973; Effects of external pneumatic intermittent compression on fibrinolysis in man. Lancet 2: 1412.
    CrossrefPubMedGoogle Scholar
  • 2 Becker J. 1972; Fibrinolytic activity of the blood and its relation to post-operative venous thrombosis of the lower limbs. Acta Chirurgica Scandinavica 138: 787.
    PubMedGoogle Scholar
  • 3 Chajek T, Aronowski E, and Izak G. 1973; Decreased fibrinolysis in Behçet’s disease. Thrombos. Diathes. haemorrh 29: 610.
    PubMedGoogle Scholar
  • 4 Chakrabarti R, Hocking E. D, and Fearnley G. R. 1965; Fibrinolytic effect of metformin in coronary-artery disease. Lancet 2: 256.
    PubMedGoogle Scholar
  • 5 Chakrabarti R, Fearnley G. R, and Hocking E. D. 1964; Effect of corticosteroid on fibrinolysis in patients with inflammatory and non-inflammatory conditions. British Medical Journal 1: 534.
    CrossrefPubMedGoogle Scholar
  • 6 Chakrabarti R, Fearnley G. R, Hocking E. D, Delitheos A, and Clarke G. M. 1966; Fibrinolytic activity in relation to age in survivors of myocardial infarction. Lancet 1: 573.
    PubMedGoogle Scholar
  • 7 Chakrabarti R, and Fearnley G. R. 1967; Reduction of platelet stickiness by phenformin plus ethyloestrenol. Lancet 2: 1012.
    PubMedGoogle Scholar
  • 8 Chakrabarti R, Hocking E. D, Fearnley G. R, Mann R. D, Attwell T. N, and Jackson D. 1968; Fibrinolytic activity and coronary-artery disease. Lancet 1: 987.
    PubMedGoogle Scholar
  • 9 Chakrabarti R, and Fearnley G. R. 1968; Effects of Clofibrate on fibrinolysis, platelet stickiness, plasma-fibrinogen and serum-cholesterol. Lancet 2: 1007.
    PubMedGoogle Scholar
  • 10 Chakrabarti R, and Fearnley G. R. 1969; Clofibrate and the fibrinolytic system. Lancet 2: 263.
    PubMedGoogle Scholar
  • 11 Chakrabarti R, Hocking E. D, and Fearnley G. R. 1969; Reaction pattern to three stresses-electroplexy, surgery, and myocardial infarction of fibrinolysis and plasma fibrinogen. Journal of Clinical Pathology 22: 659.
    CrossrefPubMedGoogle Scholar
  • 12 Chakrabarti R, Evans J. F, and Fearnley G. R. 1970; Effects on platelet stickiness and fibrinolysis of phenformin combined with ethyloestrenol or stanozolol. Lancet 1: 591.
    PubMedGoogle Scholar
  • 14 Chakrabarti R, and Fearnley G. R. 1972; Phenformin plus ethyloestrenol in survivors of myocardial infarction. Lancet 2: 556.
    PubMedGoogle Scholar
  • 15 Constantini R, HiLBE G, Spöttl F, and Holzknecht F. 1972; The plasminogen activator content of the arterial wall in occlusive arterial disease. Thrombosis et Diathesis Haemorrhagica 27: 649.
    PubMedGoogle Scholar
  • 16 Cotton R. C, and Wade E. G. 1969; Clofibrate and the fibrinolytic system. Lancet 1: 263.
    PubMedGoogle Scholar
  • 17 Cunliffe W. J. 1968; An association between cutaneous vasculitis and decreased blood fibrinolytic activity. Lancet 1: 1226.
    PubMedGoogle Scholar
  • 18 Cunliffe W. J, and Menon I. S. 1969; Treatment of Behçet’s syndrome with phenformin and ethyloestrenol. Lancet 1: 1239.
    PubMedGoogle Scholar
  • 19 Cunliffe W. J, and Menon I. S. 1971; The association between cutaneous vasculitis and decreased blood fibrinolytic activity. British Journal of Dermatology 84: 99.
    CrossrefPubMedGoogle Scholar
  • 20 Cunliffe W. J, Roberts B. E, and Dodman B. 1973; Behçet’s syndrome and oral fibrinolytic therapy. Lancet 2: 486.
    PubMedGoogle Scholar
  • 21 Davidson J. F, Lochhead M, McDonald G. A, and McNicoL G. P. 1972; Fibrinolytic enhancement with stanozolol: a double-blind trial. British Journal of Haematology 22: 543.
    CrossrefPubMedGoogle Scholar
  • 22 Desnoyers P, Labatjme J, Baudet M, and Verry M. 1971 Fibrinolytic activity of vascular endothelium demonstrated by Todd’s method, after administration of a new antidiabetic drug, 1702 SE. Abstracts II Congress on Thrombosis, Oslo, p. 118.
    PubMedGoogle Scholar
  • 23 Dodman B, Cunliffe W. J, Roberts B. E, and Sibbald R. 1973; Clinical and laboratory double-blind investigation on effects of fibrinolytic therapy in patients with cutaneous vasculitis. British Medical Journal I: 82.
    PubMedGoogle Scholar
  • 24 Farid N. R, Anderson J, Martin A, and Weightman D. 1974; Fibrinolytic activity and treatment of diabetes. Lancet 1: 631.
    PubMedGoogle Scholar
  • 25 Fearnley G. R, Chakrabarti R, and Vincent C. T. 1960; Effect of the sulphonyl-ureas on fibrinolysis. Lancet 2: 622.
    PubMedGoogle Scholar
  • 26 Fearnley G. R. 1961; A concept of natural fibrinolysis. Lancet 1: 992.
    PubMedGoogle Scholar
  • 27 Fearnley G. R, Chakrabarti R, and Avis P. R. D. 1963; Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity. Brit. Med. J 1: 921.
    CrossrefPubMedGoogle Scholar
  • 28 Fearnley G. R, and Chakrabarti R. 1964; Pharmacological enhancement of fibrinolytic activity of blood. Journal Clinical Pathology 17: 328.
    PubMedGoogle Scholar
  • 29 Fearnley G. R, Chakrabarti R, and Hocking E. D. 1965; Phenformin in rheumatoid arthritis. A fibrinolytic approach. Lancet 1: 9.
    PubMedGoogle Scholar
  • 30 Fearnley G. R, and Chakrabarti R. 1966; Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethyloestrenol. Lancet 2: 757.
    PubMedGoogle Scholar
  • 31 Fearnley G. R, Chakrabarti R, and Hocking E. D. 1967; Fibrinolytic effects of diguanides plus ethyloestrenol in occlusive vascular disease. Lancet 2: 1008.
    PubMedGoogle Scholar
  • 32 Fearnley G. R, and Chakrabarti R. 1968; Effect of ethyloestrenol combined with phenformin or with metformin on platelet stickiness and serum-cholesterol in patients with occlusive vascular disease. Lancet 2: 1004.
    PubMedGoogle Scholar
  • 33 Fossard D. P, Field E. S, Kakkar V. V, Friend J. R, Corrigan T. P, and Flute P. T. 1974; Fibrinolytic activity and post-operative deep-vein thrombosis. Lancet 1: 9.
    PubMedGoogle Scholar
  • 34 Gader A. M. A, Da Costa J, and Cash J. D. 1973; A new vasopressin analogue and fibrinolysis. Lancet 2: 1417.
    PubMedGoogle Scholar
  • 35 Goldrick R. B. 1961; Fibrinolysis, blood clotting, serum lipids and body build in natives of New Guinea and Australians. Australian Annals of Medicine 10: 20.
    PubMedGoogle Scholar
  • 36 Goodhart J. M, and Dewar H. A. 1966; Effect of Atromid-S on fibrinolytic activity in patients with ischaemic heart disease and normal blood cholesterol levels. British Medical Journal 1: 325.
    CrossrefPubMedGoogle Scholar
  • 37 Heikinheimo R. 1969; Metformin and fibrinolysis. Scandinavian Journal of Haematology 6: 288.
    PubMedGoogle Scholar
  • 38 Hocking E. D, Chakrabarti R, Evans J, and Fearnley G. R. 1967; Effect of digunides and atromid on fibrinolysis. Journal of Atherosclerosis Research 7: 121.
    CrossrefPubMedGoogle Scholar
  • 39 Innes D, and Sevitt S. 1964; Coagulation and fibrinolysis in injured patients. J. Clin. Path 17: 1.
    CrossrefPubMedGoogle Scholar
  • 40 Isacson S, Linell F, Moller H, and Nilsson I. M. 1970; Coagulation and fibrinolysis in chronic panniculitis. Acta Dermatologica et Venereologica 50: 213.
    PubMedGoogle Scholar
  • 41 Isacson S, and Nilsson I.M. 1970; Effect of treatment with combined phenformin and ethyloestrenol on the coagulation and fibrinolytic systems. Scand. J. Haemat 7: 404.
    PubMedGoogle Scholar
  • 42 Isacson S. 1971; Low fibrinolytic activity of blood and vein walls in venous thrombosis. Scandinavian Journal of Haematology Suppl. 16: 21.
    PubMedGoogle Scholar
  • 43 Isacson S, and Nilsson I. M. 1975. Effect of treatment with combined phenformin and ethyloestrenol on the fibrinolytic system in patients with recurrent “idiopathic” venous thrombosis. In: von Kaulla K. N, and Davidson J. F. (Ed.). Synthetic Fibrinolytic Thrombolytic Agents. Chemical, Biochemical, Pharmacological and Clinical Aspects. Charles C. Thomas; Springfield: (in the press)
    Google Scholar
  • 44 James D. C, Drysdale J, Billmoria J. D, Wheatley D, Gravey C. J, and Maclasan N. F. 1961; Lipaemia and blood-coagulation defects in relation to ischaemic heart disease. Lancet 2: 798.
    PubMedGoogle Scholar
  • 45 Yerstraete Katz A. M, McDonald L, Davies B, and Edgill M. 1963; Fibrinolysis and blood coagulation in ischaemic heart disease. Lancet 1: 801.
    PubMedGoogle Scholar
  • 46 Mansfield A. O. 1972; Alteration in fibrinolysis associated with surgery and venous thrombosis. British Journal of Surgery 59: 754.
    CrossrefPubMedGoogle Scholar
  • 47 Menon I. S, and Cunliffe W. J. 1969; Phenformin and ethyloestrenol for Raynaud’s disease. Lancet 2: 1135.
    PubMedGoogle Scholar
  • 48 Menon I. S, Cunliffe W. J, and Dewar H. A. 1969 Preliminary report of beneficial effect of phenformin in combination with ethyloestrenol in the treatment of cutaneous vasculitis and Behçet’s syndrome. Postgraduate Medical Journal. 45. Suppl. 62
    PubMedGoogle Scholar
  • 49 Menon I. S, Cunliffe W. J, Weightman D, and Dewar H. A. 1970; Phenformin and stanozolol in blood fibrinolytic activity. British Medical Journal 1: 428.
    PubMedGoogle Scholar
  • 50 Menon J. S, McCollum J. P, and Gibson A. L. 1971; Blood fibrinolytic activity in deep-vein thrombosis. Lancet 1: 242.
    PubMedGoogle Scholar
  • 51 Merskey C, Gordon H, Lackner H, Schrire V, Kaplan B. J, Sougin-Nlbashan P, Nossel H. L, and Moodie A. 1960; Blood coagulation and fibrinolysis in relation to coronary heart disease. British Medical Journal 1: 219.
    CrossrefPubMedGoogle Scholar
  • 52 Naimi S, Goldstein R, and Proger S. 1963; Studies on the coagulation and fibrinolysis of the arterial and venous blood in normal subjects and patients with atherosclerosis. Circulation 28: 904.
    PubMedGoogle Scholar
  • 53 Nestel P. J. 1959; Fibrinolytic activity of the blood in intermittent claudication. Lancet 2: 373.
    PubMedGoogle Scholar
  • 54 Nilsson I. M, and Isacson S. 1973 New aspects of the pathogenesis of thromboembolism. (Prog. Surg. 11, 46).
    PubMedGoogle Scholar
  • 55 Ogston D. 1962; Serum microproteins and plasma fibrinolytic activity in coronary-artery disease. British Medical Journal 1: 1242.
    CrossrefPubMedGoogle Scholar
  • 56 Pandolfi M, Nilsson I. M, Robertson B, and Isacson S. 1967; Fibrinolytic activityo of human veins. Lancet 2: 127.
    PubMedGoogle Scholar
  • 57 Pandolfi M, Hedner U, and Nilson I. M. 1970; Bilateral occlusion of the retinal veins in a patient with inhibition of fibrinolysis. Annals of Ophthalmology 1: 482.
    PubMedGoogle Scholar
  • 58 Pandolfi M, Isacson S, and Astedt B. 1972; Coagulation and fibrinolytic studies in 23 patients with occlusion of the retinal vessels. Acta Ophthalmologica 50: 60.
    PubMedGoogle Scholar
  • 59 Parish W. E. 1972; Cutaneous vasculitis: antigen-antibody complexes and prolonged fibrinolysis. Proceedings of the Royal Society of Medicine 65: 276.
    PubMedGoogle Scholar
  • 60 Rosing D. R, Redwood D. R, Brakman P, Astrup T, and Epstein S. E. 1973; Impairment of the diurnal fibrinolytic response in man. Effects of ageing, type IV hyperlipoproteinemia, and coronary artery disease. Circulation Research 32: 752.
    CrossrefPubMedGoogle Scholar
  • 61 Srivastata S. C, Smith M. J, and Dewar H. A. 1963; The effect of Atromid on fibrinolytic activity of patients with ischaemic heart disease and hypercholesterolemia. Journal of Atherosclerosis Research 3: 640.
    CrossrefPubMedGoogle Scholar
  • 62 Sweet B, Rifkind B. M, and McNicol G. P. 1965; The effect of Atromid-S on the fibrinolytic enzyme system. Journal of Atherosclerosis Research 5: 347.
    CrossrefPubMedGoogle Scholar
  • 63 Tsapogas M. J, Cotton L. T, Flute P. T, and Murray J. J. 1962; The effects of clorpropamide on intermittent claudication and fibrinolysis. Lancet 1: 1213.
    PubMedGoogle Scholar
  • 64 Verstraete M, Vermylen J, and de Gaetano G. Stimulation of the fibrinolytic system with ethyloestrenol. To be published.
    PubMedGoogle Scholar